HTFL Chief Medical Officer Campbell Rogers Sells $1.3M of Stock

On October 22, 2026, Campbell Rogers, the Chief Medical Officer of Heartflow, Inc. (NASDAQ: HTFL), sold 23,933 shares at a price of $55.01 per share, totaling about $1,309,554. This transaction was reported through a Form 4 filing with the SEC. Following the sale, Rogers holds 73,453 shares, which represents a reduction of about 24.58% in his stake.

HTFL Heartflow, Inc.

$57.01 ▲ +96.79% year to date

1M 3M YTD

Daily close · Oct 26, 2026

Other Institutional Activity in Heartflow, Inc.

Several other funds have also made adjustments to their positions in Heartflow. Bain Capital Life Sciences Investors, LLC reduced its holdings by 1,999,725 shares, bringing its total to 8,448,158 shares valued at approximately $481.6 million. BAMCO Inc. decreased its shares by 602,464, ending with 3,225,133 shares worth about $183.8 million. Conversely, Jupiter Topco LLC grew its stake by 1,209,668 shares, reaching 2,419,336 shares valued at around $137.9 million, while Alliancebernstein L.P. increased its holdings by 699,945 shares, totaling 1,924,268 shares worth about $109.7 million.

Heartflow, Inc. Stock Up 2.8%

Heartflow, Inc. shares closed at $55.43 on October 22, 2026, just above the recent trading price of about $57.01 as of October 26, 2026. This recent price is about 2.9% higher than the closing price on the date of Rogers' sale. The stock has traded well above its 50-day moving average by 15.4% and its 200-day moving average by 70.3%, indicating strong performance recently.

Recent Earnings

Heartflow, Inc. reported trailing twelve-month revenue of $212.1 million with a year-over-year growth of 47.6%. However, the company has not been profitable, posting a negative net margin of -55.8% and an earnings per share (EPS) of -0.24. The next earnings report is scheduled for November 12, 2026.

Insider Buying and Selling at Heartflow, Inc.

Earlier this year, several insiders have sold shares of Heartflow, including Chief Executive Officer John C.M. Farquhar, who sold 38,900 shares on October 12 for about $1.93 million. Additionally, Chief Financial Officer Vikram Verghese sold 34,975 shares on September 15, valued at approximately $1.75 million. These trades suggest ongoing activity among company executives.

Analysts Set New Price Targets

On October 20, 2026, Piper Sandler reiterated its Overweight rating on Heartflow, Inc. with a price target of $64. On September 22, Canaccord Genuity maintained a Buy rating, raising its target to $56. The consensus among analysts gives Heartflow a strong buy rating with a mean price target of $50.50, suggesting potential upside from current levels.

About Heartflow, Inc.

Heartflow, Inc. is a medical technology company based in San Francisco, California. It focuses on providing non-invasive solutions for diagnosing and managing coronary artery diseases. The company's HeartFlow Platform uses artificial intelligence and advanced imaging techniques to create detailed models of patients' hearts, aiding in more accurate diagnosis and treatment.

Bottom Line

Investors should watch for Heartflow's upcoming earnings report on November 12, 2026, as it may provide further insights into the company's performance. Additionally, insider transactions like Campbell Rogers' recent sale could indicate shifts in management confidence or strategy.